Picture of Iterum Therapeutics logo

ITRMF — Iterum Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Iterum Therapeutics PLC expected to post a loss of 93 cents a share - Earnings Preview

* Iterum Therapeutics PLC  ITRM.OQ   ITRM.O  is expected
to report
resultson March 14 (estimated) for the period ending December
31 2023
    * 
    * ​LSEG's mean analyst estimate for Iterum Therapeutics PLC
is for
a loss of 93 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Iterum
Therapeutics PLC is $6.50​, above​ its last closing price
of $1.62. ​​​

This summary was machine generated March 12 at 08:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Iterum Therapeutics

See all news